Study Evaluating the Efficacy and Safety of Chimeric Antigen Receptor-Modified pNK Cells in MUC1 Positive Advanced Refractory or Relapsed Solid Tumor

NCT02839954 Phase 1/Phase 2 UNKNOWN

The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.

Details

Lead sponsor	PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase	Phase 1/Phase 2
Status	UNKNOWN
Enrolment	10
Start date	2016-07
Completion	2018-07

Conditions

• Hepatocellular Carcinoma
• Non-small Cell Lung Cancer
• Pancreatic Carcinoma
• Triple-Negative Invasive Breast Carcinoma
• Malignant Glioma of Brain
• Colorectal Carcinoma
• Gastric Carcinoma

Interventions

• anti-MUC1 CAR-pNK cells

Primary outcomes

• Phase I: Adverse events attributed to the administration of the anti-MUC1 CAR-pNK cells — 2 years
  Determine the toxicity profile of the MUC1 targeted CAR-pNK cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0.

Countries

China